Andy Scharenberg, Umoja Biopharma CEO

Umo­ja to dose first pa­tient with in vi­vo CAR-T by end of this year

Umo­ja Bio­phar­ma has the FDA’s green light to dose the first pa­tient with what it be­lieves could be a more read­i­ly ac­ces­si­ble CAR-T ther­a­py. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA